StethoMe is engaged in the development of a smart stethoscope that enables home-based monitoring of respiratory sounds, particularly for patients with chronic respiratory conditions like asthma. This technology involves artificial intelligence for sound analysis.

StethoMe

Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.

Metric
Company Name	StethoMe	Masimo Corporation
Symbol		MASI
MSH ID	COM:STETHOME	COM:MASIMO
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Medical Technology	Medical - Instruments & Supplies
Country	PL	US
Stage
Employee Count		3.80K
Website	stethome.com	masimo.com
LinkedIn
Founders

Metric
Market Cap		5.69B
Enterprise Value
Monthly Web Traffic	2.76K	193.91K
Web Traffic Growth	2.15	0.29
Valuation
Raised Capital	1.21M	750M

Metric
Revenue		2.05B
Revenue (LTM)
Revenue (NTM)
Gross Profit		1.00B
EBITDA		262.60M
Operating Income		164.30M
Net Income		81.50M
EPS		1.54
Diluted EPS		1.51
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.49
Operating Profit Margin		0.08
EBITDA Margin		0.13
Net Profit Margin		0.04
Return on Equity		0.06
Return on Assets		0.03
Return on Capital Employed		0.06

STET

COM:STETHOME

StethoMe

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		79.31
P/B Ratio		5.50
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		3.84
EV Multiple		27.18

Metric
Days Sales Outstanding		61.56
Days Payables Outstanding		97.44
Days Inventory Outstanding		190.43
Operating Cycle		266.68
Cash Conversion Cycle		193.68
Asset Turnover		0.70

Metric
Operating Cash Flow		94.10M
Free Cash Flow		6.40M
Cash Flow to Debt		0.24
Operating Cash Flow/Sales		0.09
Free Cash Flow Yield		-0.01

Metric
Cash & Equivalents		166M
Accounts Receivable		91.90M
Inventory		545M
Goodwill		407.70M
Debt to Capitalization		0.41
Debt to Assets		0.32
Current Ratio		2.14
Quick Ratio		1.31

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.00
R&D to Revenue		0.09
SG&A to Revenue